Macular degeneration
Conditions
Sponsors
EyeCure Therapeutics, Inc.
Eligibility
Sex/Gender
All
Age
50 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged 50~80 years; 2. Diagnosed as atrophic macular degeneration (>250 microns of geographic atrophy involving central fovea); 3. BCVA of study eye equal to or worse than 20/200, BCVA of control eye equal to or better than 20/200; 4. Good health condition: Normal vital signs, electrocardiogram, routine blood and urine tests; 5. Understand and be able to sign the informed consent. 5. To be able to understand and willing to sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Hemoglobin1.5; creatinine level>1.3mg/dL; 3. Presence of glaucomatous optic neuropathy in the study eye; 4. Progressive Cataract causing difficulty of retina examination; 5. Any eye surgery other than cataract surgery within previous 3 months; 6. History of retina detachment repair in the study eye; 7. Uveitis or other intraocular inflammatory disease in the study eye; 8. Any other sight-threatening ocular disease; 9. Participation in any clinical trial of a drug by ocular or systemic administration within the past 6 months; 10. History of malignancy (except excised basal cell or squamous cell of skin); 11. History of myocardial infarction; 12. History of diabetes mellitus; 13. History of Parkinson's disease or Alzheimer's disease; 14. Any current immunosuppressive therapy other than intermittent or low dose corticosteroids; 15. Any other medical condition that affects patient compliance, patient safety, or the outcome of this clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Best corrected visual acuity; | — |
Secondary
| Measure | Time frame |
|---|---|
| Optical coherent tomography (OCT);mERG;fundus photography; | — |
Countries
China
Contacts
Public ContactLv Zhi-gang
EyeCure Therapeutics, Inc.
Outcome results
None listed